Minnow Street Minnow Street
Buy Day today: Poor Neutral (49) Good Mixed market breadth · no major macro event
Design (Testphase)

Breakout & Setup

Tight & Near High

133 Hits
July 21, 2026 last calculated

Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q) · showing the 25 strongest hits

Tight daily and weekly range (WCR ≥ 85, DCR ≥ 70) no more than 8% below the high — volatility contraction just under the high.

Global filters: 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); names with a red Stress RS (rating ≤ 30 — weak on stress days) are excluded.

🔔 Watch scanner

Terms in This Scanner Explained

(15)
ADR (Average Daily Range)
The average daily swing of a stock in percent - measured over 10 or 30 trading days (columns "ADR 10D/30D"). An ADR of 5% means: on a normal day the gap between the intraday low and high runs about 5%. Traders look for movement - that is why stocks with an ADR under 1% are filtered out globally. Not to be confused with ADR meaning "American Depositary Receipt" (a US certificate for foreign shares) - here ADR always means the daily swing.
AI Classification
Our company-by-company assessment of the AI boom based on SEC filings (the last four quarterly 10-Q reports and two annual 10-K reports): "Sells AI" (AI is a revenue source), "Threatened" (AI is a concrete business risk), "Uses AI" (operational use), or "Neutral" (no material AI exposure). Every classification requires at least two direct quote citations - otherwise the column shows "-". Not a quality judgment or a buy recommendation; the full file is on the stock page, methodology at /stocks/ai-rating-methodology.
Analysis (Full Company Analysis)
If the Analysis column shows "Read," there is an in-depth Minnow Street company analysis for this stock: business model, scanner findings, quarterly results, evidence from SEC filings, plus opportunities and risks. One click opens it directly.
Avg/Yr 3Y (Average Annual Return)
The stock's average annual return over the past 3 years. Shows at a glance whether a stock delivers over the long run or just had a short hot streak.
Earnings Date
The date of the next quarterly earnings report. Price gaps in either direction are common around this date - that is why we color it red when it is 7 days away or less, and yellow when it is 14 days away or less: elevated risk for fresh positions.
EPS (Earnings per Share)
Quarterly earnings divided by the number of shares outstanding. The most important growth metric: if EPS rises strongly over several quarters, the company is earning more money per share.
Free Cash Flow (FCF)
Operating cash flow minus capital expenditures - the money left over for everything else (debt paydown, acquisitions, or buybacks). Consistently positive free cash flow is one of the most honest signs of a healthy business model.
Funda Rating (Fundamental Rating A+ to F)
Our proprietary fundamental rating from -100 to +100 with a school-grade rank from A+ to F. Every stock is scored against all others by percentile: growth in earnings and revenue, earnings surprises, analyst estimates, and quality criteria such as margins, cash flow, and balance-sheet strength. A/A+ are the fundamentally strongest stocks in the universe.
Market Capitalization (Mkt Cap)
The market value of the company: share price x total shares outstanding, shown here in billions of dollars. Micro caps (< $0.3B) are small and volatile, mega caps (> $200B) are heavyweights. Our scanner universe is deliberately capped at $50B - we look for stocks with room to run.
Net Margin
How much of revenue is left as profit? Net income divided by revenue, in percent. A 20% margin means: out of every dollar of revenue, 20 cents is left as profit. Rising margins are a strong quality signal.
Operating Cash Flow (OCF)
The cash that actually flows into the company from day-to-day operations - without accounting effects such as depreciation. A company can report book profits while still burning cash; operating cash flow reveals that.
Piotroski F-Score
A balance-sheet health check developed by Joseph Piotroski: 9 yes/no criteria covering earnings, cash flow, leverage, and efficiency produce a score from 0 to 9. Scores of 7 or higher are considered financially very solid, scores under 3 a warning sign.
Sector & Industry
Two levels of industry classification: sector is broad (e.g., Technology), industry is narrow (e.g., Semiconductors). Many strategies watch industry strength, because strong stocks are almost always found in strong industries.
Stage (Weinstein Stages 1-4)
Stan Weinstein divides every price chart into four stages: Stage 1 = basing (sideways after a downtrend), Stage 2 = uptrend (the only buying stage), Stage 3 = topping, Stage 4 = downtrend (avoid, or short candidate). Measured against the 30-week line (150-day moving average) and its slope.
Stress RS (Strength on Stress Days)
A stress day is a day on which both the overall market and the stock's own sector fell at least 0.5%. Stress RS counts on how many of these days the stock still closed green (shown as "g/n" = green days out of n stress days) and turns that into a rating from 1 to 99. High values point to buyers stepping in even on weak days - often a sign of institutional accumulation.

Hit List

Filter

Rating (traffic light)

Stage

Funda Rating

Piotroski

Columns ▾

This scanner's columns

Extra columns

Tip: clicking a column header sorts the table by that column; a second click flips the direction.

Tight & Near High
Symbol Earnings Avg/Y 3Y Stress RS Stage Funda Rating Piotroski MktCap Industry AI Rating Deep Dive Deep-Dive Report Sector Price YTD 6 Mo. 1 Year Off High Price Target RS EPS Rating ADR 10D ADR 30D Beta P/E P/E (f) P/S P/B P/FCF PEG EV/EBITDA EBIT Margin Gross Margin Net Margin ROE ROA Debt/Eq Equity Ratio Sales +/Y Div. Yield Payout Ratio Altman Z Inst. % Short % Analysts
SLS Sellas Life Sciences Group Inc 08/11 +148 % Stage 2 C +5 3 of 9 0.0 Biotechnology Healthcare 12.50 $ +140.6 % +444.0 % +436.3 % −4.8 % -5.0 % 98 50 12.4 % 11.1 % 2.43 0.0 -1.7 0.0 % 0.0 % -43.6 % -25.5 % 94.1 % -100.0 % 0.0 % 0.0 % 16.0 27.6 % 32.4 % 1.0 (3)
RVMD Revolution Medicines Inc 08/05 +188 % 38 4/22 Stage 2 D -18 1 of 9 37.1 Biotechnology Healthcare 180.40 $ +112.8 % +137.2 % +324.0 % −3.4 % +10.7 % 97 42 4.8 % 4.4 % 1.38 0.0 25.8 -9.7 0.0 % -151,691.8 % 0.0 % -76.7 % -37.5 % 0.29 66.6 % -100.0 % 0.0 % 0.0 % 1.4 95.7 % 6.1 % 1.0 (12)
RLAY Relay Therapeutics Inc 08/06 +16 % 88 8/22 Stage 2 D -48 3 of 9 3.9 Biotechnology Healthcare 19.20 $ +106.1 % +128.2 % +457.9 % −5.9 % +39.2 % 97 42 6.4 % 8.1 % 1.68 0.0 360.2 -0.8 -2,619.7 % -2,300.3 % 0.0 % -40.0 % -24.7 % 91.8 % +53.4 % 0.0 % 0.0 % 8.5 87.0 % 20.4 % 1.2 (13)
MBX MBX Biosciences, Inc. Common Stock 08/06 69 6/22 Stage 2 D -33 3 of 9 2.3 Biotechnology Healthcare 60.10 $ +47.1 % +67.7 % +397.4 % −4.1 % +37.2 % 97 42 8.5 % 7.7 % 0.0 5.5 0.0 0.0 % 0.0 % -25.7 % -17.7 % 0.00 96.7 % 0.0 % 0.0 % 37.2 111.5 % 16.8 % 1.0 (5)
TH Target Hospitality Corp 08/06 +18 % 96 13/29 Stage 2 D -12 4 of 9 2.0 Specialty Business Services Sells AI Industrials 16.40 $ +156.2 % +142.8 % +181.0 % −3.1 % +9.0 % 96 12 4.0 % 4.1 % 1.46 20.2 6.2 5.3 33.7 1.34 69.0 28.0 % -13.5 % -11.0 % -5.0 % 0.10 -17.0 % 0.0 % 0.0 % 6.7 78.8 % 10.0 %
ELVN Enliven Therapeutics Inc. 08/12 +44 % 69 6/22 Stage 2 D -44 4 of 9 3.3 Biotechnology Healthcare 51.70 $ +215.6 % +203.9 % +135.4 % −2.8 % +32.6 % 95 42 6.6 % 6.9 % 0.26 0.0 7.9 -6.3 0.0 % 0.0 % -26.6 % -18.9 % 0.00 97.5 % 0.0 % 0.0 % 47.0 89.7 % 11.1 % 1.0 (8)
NVCT Nuvectis Pharma Inc 08/04 +1 % 82 7/22 Stage 2 E -54 1 of 9 0.9 Biotechnology Healthcare 18.00 $ +132.5 % +270.0 % +207.5 % −0.2 % +4.8 % 95 42 16.4 % 9.8 % -0.25 0.0 -7.4 0.0 % -154.4 % -63.6 % -100.0 % 0.0 % 0.0 % -7.1 18.2 % 10.1 %
OSCR Oscar Health Inc 08/05 +84 % 79 7/22 Stage 2 B +28 7 of 9 8.2 Healthcare Plans Uses AI Healthcare 29.60 $ +108.3 % +97.3 % +42.8 % −5.6 % -21.2 % 94 87 5.6 % 6.6 % 2.34 588.2 0.6 5.3 2.9 0.0 15.2 % 17.4 % -0.3 % -2.6 % 0.1 % 0.26 17.9 % +27.5 % 0.0 % 0.0 % 3.0 67.6 % 7.1 % 1.9 (7)
URGN UroGen Pharma Ltd 08/06 +18 % 69 6/22 Stage 2 B +13 3 of 9 1.7 Biotechnology Uses AI Healthcare 41.10 $ +50.1 % +51.8 % +147.7 % −4.7 % +8.0 % 94 42 5.1 % 5.4 % 1.58 0.0 11.8 -2.6 -39.8 % 89.9 % -94.8 % -1,481.3 % -27.0 % -49.0 % +21.5 % 0.0 % 0.0 % -8.0 100.6 % 13.7 % 1.3 (8)
RCUS Arcus Biosciences Inc 08/05 +16 % 40 4/22 Stage 2 D -34 0 of 9 3.8 Biotechnology Neutral Healthcare 28.20 $ +18.3 % +34.4 % +233.7 % −3.8 % +18.2 % 93 42 6.2 % 6.0 % 0.80 0.0 16.1 7.4 4.0 -788.2 % -121.6 % -156.4 % -70.0 % -23.1 % 0.22 52.6 % -4.3 % 0.0 % 0.0 % 1.0 72.4 % 17.4 % 1.2 (13)
CGEM Cullinan Oncology LLC 08/06 +14 % 55 5/22 Stage 2 C -6 1 of 9 1.1 Biotechnology Healthcare 17.50 $ +71.5 % +79.5 % +132.9 % −1.5 % +70.7 % 93 42 8.3 % 8.2 % -0.01 6.7 -1.5 0.0 % -48.2 % -30.6 % -100.0 % 0.0 % 0.0 % 10.2 107.8 % 18.9 %
MRX Marex Group plc Ordinary Shares 08/12 79 7/22 Stage 2 B +21 4 of 9 4.5 Capital Markets Financial Services 62.60 $ +74.6 % +49.3 % +72.9 % −4.8 % -7.8 % 92 79 4.9 % 4.7 % -0.09 14.5 8.8 0.8 3.4 6.1 13.1 % 68.9 % 10.6 % 29.1 % 1.1 % 3.7 % +25.4 % 1.0 % 13.3 % 4.2 75.2 % 4.6 % 1.1 (8)
NAT Nordic American Tankers Limited +50 % 98 5/10 Stage 2 C +9 7 of 9 1.3 Oil & Gas Midstream Energy 6.20 $ +102.0 % +83.4 % +168.5 % −6.6 % -4.2 % 92 97 5.9 % 4.4 % -0.55 10.0 3.8 1.21 17.3 49.5 % 46.9 % 16.4 % 11.4 % 4.7 % 50.6 % -16.4 % 15.2 % 3.4 % 6.0 50.0 % 10.9 % 1.7 (3)
KGS Kodiak Gas Services, Inc. 08/05 98 5/10 Stage 2 B +11 7 of 9 7.4 Oil & Gas Equipment & Servic Energy 64.50 $ +94.9 % +106.1 % +116.8 % −4.8 % +13.7 % 91 17 4.1 % 3.8 % 0.82 93.0 32.1 5.6 6.4 36.8 17.7 33.7 % 64.2 % 5.1 % 5.4 % 6.0 % 0.06 26.1 % +12.8 % 2.8 % 120.8 % 4.2 91.3 % 8.5 % 1.2 (11)
DHC Diversified Healthcare Trust 08/03 +127 % 44 4/21 Stage 2 D -19 4 of 9 2.2 REIT - Healthcare Facilities Uses AI Real Estate 9.10 $ +89.0 % +97.1 % +156.5 % −0.5 % +4.7 % 91 9 4.3 % 4.0 % 2.27 16.6 1.5 1.4 1.89 51.8 -1.3 % 17.7 % -21.1 % -17.9 % -0.5 % 1.49 38.0 % +2.8 % 0.4 % 2.3 % 1.6 84.3 % 4.7 % 2.0 (3)
ESOA Energy Services Of America Corp 08/10 +201 % 96 13/29 Stage 2 B +27 9 of 9 0.3 Engineering & Construction Neutral Industrials 15.90 $ +126.3 % +137.4 % +86.5 % −6.2 % +47.1 % 91 91 5.3 % 5.4 % 1.33 34.4 25.1 0.8 4.3 35.9 11.7 11.9 % 2.1 % 13.7 % 5.7 % 0.46 +16.8 % 0.9 % 24.1 % 5.7 55.5 % 2.7 %
ALKS Alkermes Plc 08/04 +15 % 68 6/22 Stage 2 C 0 1 of 9 8.8 Drug Manufacturers - Special Healthcare 51.70 $ +71.8 % +84.2 % +72.4 % −1.6 % -5.0 % 90 9 4.8 % 4.2 % 0.29 61.2 142.9 5.6 5.3 39.7 1.96 36.8 -0.2 % 87.5 % 9.8 % 9.4 % 4.7 % 0.90 41.1 % -5.3 % 0.0 % 0.0 % 4.9 110.5 % 15.0 % 1.4 (15)
INDV Indivior PLC Ordinary Shares 07/30 +25 % 68 6/22 Stage 2 B +22 4 of 9 4.7 Drug Manufacturers - Special Neutral Healthcare 39.10 $ +11.4 % +14.1 % +197.3 % −1.9 % +23.1 % 90 83 3.6 % 3.6 % 1.15 21.5 13.0 3.6 145.3 14.2 46.1 % 85.0 % 19.5 % 12.2 % 22.7 % -3.49 -12.0 % +4.3 % 0.0 % 0.0 % 3.6 107.5 % 11.9 % 1.0 (7)
FSTR LB Foster Company 08/10 +74 % 37 5/29 Stage 2 C +5 6 of 9 0.5 Railroads Industrials 41.70 $ +63.0 % +59.5 % +111.1 % −2.6 % -10.4 % 90 4 3.9 % 4.2 % 1.14 43.5 30.4 0.8 2.7 13.4 0.36 13.8 21.5 % 2.0 % 6.4 % 5.4 % 0.48 +1.7 % 0.0 % 0.0 % 8.4 72.3 % 3.0 %
LGND Ligand Pharmaceuticals Incorporate 08/06 +94 % 54 5/22 Stage 2 B +16 5 of 9 5.6 Biotechnology Healthcare 294.00 $ +47.8 % +59.3 % +147.8 % −1.4 % -6.2 % 89 86 5.6 % 4.1 % 0.98 39.5 35.8 20.3 6.1 45.2 1.53 27.1 33.6 % 83.2 % 56.0 % 17.1 % 5.2 % 0.51 65.1 % +60.4 % 0.0 % 0.0 % 10.8 106.4 % 10.1 % 1.0 (7)
ASTH Astrana Health Inc 08/06 +13 % 70 6/22 Stage 2 B +24 5 of 9 2.2 Medical Care Facilities Uses AI Healthcare 44.60 $ +66.1 % +79.3 % +68.6 % −0.5 % +8.3 % 89 87 3.6 % 3.8 % 0.89 23.0 0.6 13.9 18.6 3.0 % 10.7 % 0.9 % 5.7 % 3.6 % 33.9 % +56.4 % 0.0 % 0.0 % 5.2 61.5 % 9.1 % 1.3 (12)
WTTR Select Energy Services Inc 08/04 +56 % 56 2/10 Stage 2 C +3 6 of 9 2.7 Oil & Gas Equipment & Servic Energy 20.40 $ +78.1 % +85.5 % +112.6 % −6.4 % +17.3 % 89 30 3.5 % 3.8 % 0.96 91.2 38.3 1.9 2.4 10.5 6.5 % 28.1 % 1.5 % 2.1 % 1.7 % 0.29 58.1 % -3.1 % 1.6 % 75.3 % 5.6 97.7 % 3.5 % 1.0 (5)
CARE Carter Bank and Trust 07/23 +38 % 69 6/22 Stage 2 B +24 7 of 9 0.7 Banks - Regional Financial Services 33.00 $ +65.1 % +68.4 % +92.7 % −1.1 % -14.3 % 89 96 2.7 % 2.8 % 0.51 12.9 2.3 2.2 0.0 100.0 % 41.8 % 23.9 % 2.3 % +6.2 % 1.2 % 6.8 % -1.9 59.2 % 6.6 %
CYTK Cytokinetics Inc 08/06 +8 % 68 6/22 Stage 2 D -22 3 of 9 10.9 Biotechnology Neutral Healthcare 79.10 $ +25.9 % +36.0 % +148.8 % −2.6 % +33.5 % 88 42 4.6 % 4.1 % 0.42 117.6 102.5 60.3 -15.8 -948.7 % -290.7 % 0.0 % -572.2 % -31.5 % -1.56 -64.9 % +376.6 % 0.0 % 0.0 % -7.3 118.8 % 16.8 % 1.1 (21)
ECPG Encore Capital Group Inc 08/05 +28 % 40 4/22 Stage 2 B +47 8 of 9 1.9 Credit Services Financial Services 88.70 $ +58.0 % +68.8 % +123.5 % −5.7 % +29.7 % 88 85 3.3 % 3.2 % 1.27 4.0 1.0 11.3 0.17 8.2 38.7 % 100.0 % 16.0 % 32.0 % 8.2 % 19.0 % +33.9 % 0.0 % 0.0 % 4.3 109.6 % 7.6 % 1.2 (5)

Price Chart

Quarterly Figures

No quarterly data available.

Frequently Asked Questions

Tight daily and weekly range (WCR ≥ 85, DCR ≥ 70) no more than 8% below the high — volatility contraction just under the high.

All scanners are recalculated daily across the entire stock universe — most recently on 21. July 2026. The data basis is fundamental data and SEC filings (10-K annual reports and 10-Q quarterly reports).

Currently, 133 stocks pass this scanner's criteria (as of 21. July 2026). The 25 strongest hits are shown.

Global filters: 10- and 30-day ADR must be ≥ 1% (too little movement gets cut); names with a red Stress RS (rating ≤ 30 — weak on stress days) are excluded.

Related scanners

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?